Magnetically targeted viral envelopes: a PET investigation of initial biodistribution.
Gene and drug therapy for organ-specific diseases in part depends on the efficient delivery to a particular region of the body. We examined the biodistribution of a viral envelope commonly used as a nanoscale gene delivery vehicle using positron emission tomography (PET) and investigated the magnetic alteration of its biodistribution. Iron oxide nanoparticles and (18)F-fluoride were encapsulated by hemagglutinating virus of Japan envelopes (HVJ-Es). HVJ-Es were then injected intravenously in the rat and imaged dynamically using high-resolution PET. Control subjects received injections of encapsulated materials alone. For magnetic targeting, permanent magnets were fixed on the head during the scan. Based on the quantitative analysis of PET images, HVJ-Es accumulated in the liver and spleen and activity remained higher than control subjects for 2 h. Histological sections of the liver confirmed imaging findings. Pixel-wise activity patterns on coregistered PET images of the head showed a significantly different pattern for the subjects receiving magnetic targeting as compared to all control groups. Imaging demonstrated the initial biodistribution of a viral envelope within the rodent by providing quantitative behavior over time and in specific anatomical regions. Magnetic force altered the biodistribution of the viral envelope to a target structure, and could enable region-specific delivery of therapeutic vehicles noninvasively.
Flexman
Jennifer A
JA
Department of Bioengineering, University of Washington, Seattle, WA 98195-5061, USA.
Cross
Donna J
DJ
Lewellen
Barbara L
BL
Miyoshi
Sosuke
S
Kim
Yongmin
Y
Minoshima
Satoshi
S
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D008099:Liver / Q000000981:diagnostic imaging / Q000378:metabolism*; D008280:Magnetics; D008297:Male; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D029082:Sendai virus / Q000378:metabolism*; D013154:Spleen / Q000000981:diagnostic imaging / Q000378:metabolism*; D014018:Tissue Distribution; D014759:Viral Envelope Proteins / Q000493:pharmacokinetics*
D019275:Radiopharmaceuticals; D014759:Viral Envelope Proteins; D019788:Fluorodeoxyglucose F18
J Virol. 2002 May;76(10):5271-3
11967341
Mol Hum Reprod. 2003 Oct;9(10):603-9
12970398
Int J Cancer. 2004 Apr 20;109(4):627-35
14991586
J Drug Target. 2002 Jun;10(4):345-52
12164383
Hum Gene Ther. 2001 Mar 20;12(5):469-87
11268281
J Immunol Methods. 2002 Feb 1;260(1-2):137-48
11792384
Int J Oncol. 2001 Jan;18(1):121-5
11115548
IEEE Eng Med Biol Mag. 2006 Jul-Aug;25(4):70-5
16898661
J Nucl Med. 1998 Nov;39(11):2003-11
9829598
Methods. 2004 Jun;33(2):95-103
15121163
IEEE Trans Med Imaging. 1997 Apr;16(2):187-98
9101328
Mol Ther. 2005 Sep;12(3):384-93
15993650
Lab Invest. 1994 Dec;71(6):895-903
7807971
Mol Imaging Biol. 2005 Jul-Aug;7(4):286-95
16080022
J Drug Target. 2003 Apr;11(3):139-49
13129824
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1121-6
16134237
J Nucl Med. 1997 Dec;38(12):1970-6
9430479
Magn Reson Med. 1993 May;29(5):599-604
8505895
Biochem Biophys Res Commun. 2003 Jan 10;300(2):464-71
12504107
Cancer Chemother Pharmacol. 2003 Jun;51(6):445-50
12802508
Crit Rev Oncol Hematol. 2001 Jun;38(3):177-92
11369253
Circulation. 2003 Oct 28;108(17):2127-33
14530205
J Biosci Bioeng. 2005 Jul;100(1):1-11
16233845
Gene Ther. 2006 Feb;13(4):283-7
16462855
Prostate. 2003 Apr 1;55(1):39-47
12640659
J Control Release. 1999 May 1;59(1):15-22
10210718
Biochim Biophys Acta. 1999 Feb 16;1444(2):171-90
10023051
Hum Gene Ther. 2000 Mar 1;11(4):621-7
10724040